Age, mo, median (IQR) |
2 (0-6.3) |
1 (0-3.0) |
0.409 |
Gender, male, n (%) |
13 (43) |
40 (56) |
0.260 |
Gestational age, days, median, (IQR) |
260 (238-276) |
270 (258-280) |
0.020* |
Weight at birth, gr, median, (IQR) |
2850 (1795-3250) |
3070 (2531-3428) |
0.059 |
Previous administration of palivizumab, n (%) |
3 (10) |
4 (6) |
0.385 |
Apneas a, n (%) |
11 (37) |
23 (32) |
0.712 |
Pulmonary disease b, n (%) |
1 (3) |
0 (0) |
0.120 |
Heart disease c, n (%) |
5 (17) |
6 (8) |
0.216 |
Nursery school enrollment, n (%) |
3 (10) |
5 (7) |
0.674 |
Siblings, n (%) |
7 (23) |
17 (24) |
0.830 |
PICU admission HR, bpm, median, (IQR) |
160 (145-175) |
165 (150-180) |
0.136 |
PICU admission systolic blood pressure, mmHg, median, (IQR) |
103
(90-118) |
97 (85-110) |
0.245 |
PICU admission RR, bpm, median, (IQR) |
45 (35-61) |
40 (34-60) |
0.596 |
PICU admission score Wood-Downes-Ferresd modified,
median, (IQR) |
7 (5-9) |
7 (5-8) |
0.549 |